ELI LILLY & Co is 368.3x more valuable than Arcutis Biotherapeutics, Inc. by market capitalization ($1.070 T vs $2.91 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | ARQT | LLY |
|---|---|---|
| Market cap | $2.91 B | $1.070 T |
| US-listed rank | #1831 | #10 |
| Revenue (latest FY) | $376.07M | $65.18B |
| Net income (latest FY) | -$16.14M | $20.64B |
| Net margin | -4.3% | 31.7% |
| P/E (trailing FY) | - | 51.8 |
| SEC filings | 798 | 989 |
ELI LILLY & Co is 368.3x more valuable than Arcutis Biotherapeutics, Inc. by market capitalization ($1.070 T vs $2.91 B).
In their latest fiscal years, Arcutis Biotherapeutics, Inc. reported $376.07M in revenue while ELI LILLY & Co reported $65.18B.
Full pages: Arcutis Biotherapeutics, Inc. and ELI LILLY & Co, or browse the full rankings.